stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) Free cash flow
CG Oncology, Inc.'s free cash flow for fiscal 2025 was −$132.5M, compared with −$78.9M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$189.2M. Free cash flow has fallen for 3 consecutive fiscal years. CG Oncology, Inc. ranks 530th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$132.5M | — |
| FY2024 | −$78.9M | — |
| FY2023 | −$45.7M | — |
| FY2022 | −$29.8M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$48.8M | — |
| Jun 2026 | −$46.9M | — |
| Mar 2026 | −$57.2M | — |
| Dec 2025 | −$36.2M | — |
| 12 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| LGND Ligand Pharmaceuticals Incorporated compare | $79.8M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$66.6M |
| MANE Veradermics Incorporated compare | −$123.0M |
| KOD Kodiak Sciences Inc. compare | −$159.9M |
| CGON CG Oncology, Inc. | −$179.3M |
| PTCT PTC Therapeutics, Inc. compare | −$259.2M |
| SRRK Scholar Rock Holding Corporation compare | −$297.0M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$308.9M |
| IMVT Immunovant, Inc. compare | −$414.3M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement